Givinostat

Givinostat
Clinical data
Trade namesDuvyzat
Other namesITF-2357; ITF2357
AHFS/Drugs.comMonograph
MedlinePlusa624025
License data
Routes of
administration
Oral (suspension)
Drug classHistone deacetylase inhibitor
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityUnknown
Protein binding96%
MetabolismExtensive (not CYP450 or UGT)
Onset of action2–3 hours (TmaxTooltip time to peak levels)
Elimination half-life~6 hours
ExcretionUrine: <3% unchanged
Identifiers
  • {6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard100.258.524
Chemical and physical data
FormulaC24H27N3O4
Molar mass421.497 g·mol−1
3D model (JSmol)
  • O=C(OCc2cc1ccc(cc1cc2)CN(CC)CC)Nc3ccc(cc3)C(=O)NO
  • InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28) X markN
  • Key:YALNUENQHAQXEA-UHFFFAOYSA-N X markN
 X markNcheckY (what is this?)  (verify)

Givinostat, sold under the brand name Duvyzat is a medication used for the treatment of Duchenne muscular dystrophy. It is a histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities. It works by targeting pathogenic processes to reduce inflammation and loss of muscle.

The most common side effects include diarrhea, abdominal pain, low platelets (thrombocytopenia), nausea and vomiting, an increase in triglycerides (a type of fat in the body) (hypertriglyceridemia), and fever.

Givinostat was approved for medical use in the United States in March 2024. Givinostat is the first nonsteroidal medication approved by the US Food and Drug Administration (FDA) to treat people with all genetic variants of Duchenne muscular dystrophy. The FDA considers it to be a first-in-class medication.